Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, gaining access to an experimental drug for flu prevention in its effort to diversify ahead of patent loss for its blockbuster cancer drug Keytruda.
November 14, 2025 - 15:50
By Pharos Investment Advisors Comments are Off
Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, gaining access to an experimental drug for flu prevention in its effort to diversify ahead of patent loss for its blockbuster cancer drug Keytruda.
Regulated by Hellenic Capital Market Commission
with Registration Number 5/700/10.12.2014

Copyright 2023©. All Rights Reserved